Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia

Bibliography

• Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010;24:203-19
   PubMed Web of Science ®Google Scholar
• Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000;95(2):415-18
   PubMed Web of Science ®Google Scholar
• Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004;169:994-1000
   PubMed Web of Science ®Google Scholar
• Verkerk MM, Shovlin CL, Lund VJ. Silent threat? A retrospective study of screening practices for pulmonary arteriovenous malformations in patients with hereditary haemorrhagic telangiectasia. Rhinology 2012;50:277-83
   PubMed Web of Science ®Google Scholar
• Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol 2008;48:811-20
   PubMed Web of Science ®Google Scholar
• Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005;47(10):711-20
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000;343:931-6
   PubMed Web of Science ®Google Scholar
• Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 2010;8:1447-56
   PubMed Web of Science ®Google Scholar
• McDonald J, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia. Haematologica 2005;90:728-32
   PubMed Web of Science ®Google Scholar
• Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008;63:259-66
   PubMed Web of Science ®Google Scholar
• Shovlin C, Bamford K, Wray D. Post-NICE 2008: antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008;205:531-3
   PubMed Web of Science ®Google Scholar
• Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999;13:319-22
   PubMedGoogle Scholar
• Hitchings AE, Lennox PA, Lund VJ, Howard DJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005;19:75-8
   PubMedGoogle Scholar
• Bergler W, Sadick H, Gotte K, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002;111(3 Pt 1):222-8
   PubMed Web of Science ®Google Scholar
• Kühnel TS, Wagner BH, Schurr CP, Strutz J. Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 2005;19:508-13
   PubMedGoogle Scholar
• Faughnan ME, Palda VA, Garcia-Tsao G, et al. HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48:73-87
   PubMed Web of Science ®Google Scholar
• Sadick H, Bergler WF, Oulmi-Kagermann J, et al. Estriol induced squamous metaplasia on the nasal mucosa in patients with hereditary hemorrhagic telangiectasia. Arch Med Res 2005;36:468-73
   PubMed Web of Science ®Google Scholar
• Yaniv E, Preis M, Shevro J, et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology 2011;49:214-16
   PubMed Web of Science ®Google Scholar
• Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001;161:767
   PubMed Web of Science ®Google Scholar
• Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009;17:860-71
   PubMed Web of Science ®Google Scholar
• Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005;90:818-28
   PubMed Web of Science ®Google Scholar
• Giordano P, Lenato GM, Pierucci P, et al. Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia. J Pediatr Hematol Oncol 2009;31:577-82
   PubMed Web of Science ®Google Scholar
• Genetech. Avastin (bevacizumab) product insert. Available from: http://www.gene.com/download/pdf/avastin_prescribing.pdf
   Google Scholar
• CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 2011;305:487-94
   PubMed Web of Science ®Google Scholar
• Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-4
   PubMed Web of Science ®Google Scholar
• Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2010;364:688-9
   Web of Science ®Google Scholar
• Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;361:931
   PubMedGoogle Scholar
• Suppressa P, Liso A, Sabbà C. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol 2011;152:365
   PubMedGoogle Scholar
• Fodstad P, Dheyauldeen S, Rinde M, Bachmann-Harildstad G. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011;90:611-12
   PubMed Web of Science ®Google Scholar
• Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631-2
   PubMed Web of Science ®Google Scholar
• Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008;14:210-13
   PubMed Web of Science ®Google Scholar
• Fleagle JM, Bobba RK, Kardinal CG, et al. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Am J Med Sci 2012;343:249-51
   PubMed Web of Science ®Google Scholar
• Amanzada A, Töppler GJ, Cameron S, et al. A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab. Case Rep Oncol 2010;3:463-70
   PubMedGoogle Scholar
• Lazaraki G, Akriviadis E, Pilpilidis I, et al. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2011;106:2204-6
   PubMed Web of Science ®Google Scholar
• Brinkerhoff BT, Choong NW, Treisman JS, et al. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2012;33:349-51
   PubMed Web of Science ®Google Scholar
• Retornaz F, Rinaldi Y, Duvoux C. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;361:931
   PubMedGoogle Scholar
• Lupu A, Stefanescu C, Treton X, et al. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2013;47:256-7
   PubMed Web of Science ®Google Scholar
• Chavan A, Schumann-Binarsch S, Luthe L, et al. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Vasa 2013;42:106-10
   PubMed Web of Science ®Google Scholar
• Vlachou PA, Colak E, Koculym A, et al. Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab. J Hepatol 2013;59:816-9
   Google Scholar
• Cruikshank RP, Chern BW. Bevacizumab and hereditary haemorrhagic telangiectasia. Med J Aust 2011;194:324-5
   PubMed Web of Science ®Google Scholar
• Jamshidi N, Miller FJ, Mandel J, et al. Individualized therapy of HHT driven by network analysis of metabolomic profiles. BMC Syst Biol 2011;5:200
   PubMedGoogle Scholar
• Föllner S, Ibe M, Schreiber J. Bevacizumab treatment in hereditary hemorrhagic teleangiectasia. Eur J Clin Pharmacol 2012;68:1685-6
   PubMed Web of Science ®Google Scholar
• Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307:948-55
   PubMed Web of Science ®Google Scholar
• Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7
   PubMed Web of Science ®Google Scholar
• Dheyauldeen S, Østertun Geirdal A, Osnes T, et al. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope 2012;122:1210-14
   PubMed Web of Science ®Google Scholar
• Guldmann R, Dupret A, Nivoix Y, et al. Bevacizumab nasal spray: noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope 2012;122:953-5
   Google Scholar
• Karnezis TT, Davidson TM. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011;121:636-8
   Google Scholar
• Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012;122:495-7
   PubMed Web of Science ®Google Scholar
• Simonds J, Miller F, Mandel J, et al. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009;119:988-92
   Google Scholar
• Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2012;269:531-6
   Google Scholar
• Chen S, Karnezis T, Davidson TM. Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011;12:644-6
   Google Scholar
• Olitsky SE. Topical timolol for the treatment of epistaxis in hereditaryhemorrhagic telangiectasia. Am J Otolaryngol 2012;33:375-6
   PubMed Web of Science ®Google Scholar
• Kaja S, Hildenberg JD, Everett E, et al. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Hum Antibodies 2011;20:95-101
   PubMedGoogle Scholar